{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T06:21:14Z","timestamp":1778221274098,"version":"3.51.4"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>The aim of this study was to analyze the clinical outcome of the use of botulinum toxin type A (BTX) intramuscular injections to the head and neck, particularly the masticatory muscles of patients with temporomandibular disorder (TMD).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The medical records of all patients who had received intramuscular BTX injections between 2005 and 2018 at P\u00e4ij\u00e4t- H\u00e4me Central Hospital, Lahti, Finland were analyzed retrospectively. Gender, age, previous medical history, number of injections, injection areas, and therapeutic results were collected and analyzed. The outcome was divided into three categories based on the patients\u2019 subjective reports: not beneficial, beneficial, and highly beneficial.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 68 patients had received intramuscular BTX injections in our unit for TMD symptoms. Clinical effectiveness could be analyzed from 63 patients. Overall, 87% of them reported f\u00e4vorable outcomes. 8 (13%) reported BTX injections as not beneficial, 15 (24%) as beneficial, and 40 patients (63%) as highly beneficial.<\/jats:p>\n            <jats:p>Most patients had already received conventional treatment with an occlusal splint (93%) combined with pain medication (60%) in the primary care units before they were referred to our hospital.<\/jats:p>\n            <jats:p>There were 59 (83%) female patients, and they responded better to BTX therapy than the male patients: 91% versus 57% <jats:italic toggle=\"yes\">(P<\/jats:italic> value\u200a=\u200a0.04). Average age at the first BTX injection visit was 44.6\u200ayears (range 17.8\u201377.2). Most commonly (65%), BTX was divided bilaterally to the masseter and temporalis muscles.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>BTX injections had good therapeutic outcomes for our TMD patients. However, most patients require multiple injection visits.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/scs.0000000000008331","type":"journal-article","created":{"date-parts":[[2021,11,7]],"date-time":"2021-11-07T18:06:39Z","timestamp":1636308399000},"page":"1159-1161","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Temporomandibular Disorder Patients Benefit From Intramuscular Botulinum Toxin Type a Injections"],"prefix":"10.1097","volume":"33","author":[{"given":"Erkka","family":"Oksanen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ville","family":"M\u00e4nnist\u00f6","sequence":"additional","affiliation":[{"name":"P\u00e4ij\u00e4t-H\u00e4me Joint Authority for Health and Wellbeing, P\u00e4ij\u00e4t- H\u00e4me Central Hospital, Keskussairaalankatu 7, Lahti"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eeva","family":"Kormi","sequence":"additional","affiliation":[{"name":"P\u00e4ij\u00e4t-H\u00e4me Joint Authority for Health and Wellbeing, P\u00e4ij\u00e4t- H\u00e4me Central Hospital, Keskussairaalankatu 7, Lahti"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Vallioniemi","sequence":"additional","affiliation":[{"name":"P\u00e4ij\u00e4t-H\u00e4me Joint Authority for Health and Wellbeing, P\u00e4ij\u00e4t- H\u00e4me Central Hospital, Keskussairaalankatu 7, Lahti"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juho","family":"Suojanen","sequence":"additional","affiliation":[{"name":"P\u00e4ij\u00e4t-H\u00e4me Joint Authority for Health and Wellbeing, P\u00e4ij\u00e4t- H\u00e4me Central Hospital, Keskussairaalankatu 7, Lahti"},{"name":"Cleft Palate and Craniofacial Centre, Department of Plastic Surgery, Helsinki University Hospital and University of Helsinki, Finland. Topeliuksenk\u00e4tu 35, 00029 HUS, Finland."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,11,5]]},"reference":[{"key":"R1-20250803","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/00016357.2020.1746395","article-title":"Prevalence of clinical signs and pain symptoms of temporomandibular disorders and associated factors in adult Finns","volume":"78","author":"Qvintus","year":"2020","journal-title":"Acta Odontol Scand"},{"key":"R2-20250803","first-page":"208","article-title":"Occurrence of clinical signs of temporomandibular disorders in adult Finns","volume":"20","author":"Rutkiewicz","year":"2006","journal-title":"J Orofac Pain"},{"key":"R3-20250803","first-page":"29","article-title":"Gender difference in symptoms related to temporomandibular disorders in a population of 50- year-old subjects","volume":"17","author":"Johansson","year":"2003","journal-title":"J Orofac Pain"},{"key":"R4-20250803","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/00016350310004089","article-title":"Temporomandibular joint related painless symptoms, orofacial pain, neck pain, headache, and psychosocial factors among non-patients","volume":"61","author":"Rantala","year":"2003","journal-title":"Acta Odontol Scand"},{"key":"R5-20250803","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.oooo.2019.02.023","article-title":"Comorbidity between fibromyalgia and temporomandibular disorders: a systematic review","volume":"128","author":"Ayouni","year":"2019","journal-title":"Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology"},{"key":"R6-20250803","doi-asserted-by":"crossref","first-page":"644","DOI":"10.3109\/00016357.2012.704067","article-title":"Association of depressiveness with chronic facial pain: A longitudinal study","volume":"71","author":"Sipil\u00e4","year":"2013","journal-title":"Acta Odontol Scand"},{"key":"R7-20250803","first-page":"378","article-title":"Diagnosis and Treatment of Temporomandibular Disorders","volume":"91","author":"Gauer","year":"2015","journal-title":"American family physician"},{"key":"R8-20250803","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1600-0501.2007.01480.x","article-title":"Is there a superiority of multimodal as opposed to simple therapy in patients with temporomandibular disorders? A qualitative systematic review of the literature","volume":"18","author":"T\u00fcrp","year":"2007","journal-title":"Clin Oral Implants Res"},{"key":"R9-20250803","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.resmic.2014.09.007","article-title":"Historical and current perspectives on Clostridium botulinum diversity","volume":"166","author":"Smith","year":"2015","journal-title":"Res Microbiol"},{"key":"R10-20250803","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3390\/toxins10120535","article-title":"AbobotulinumtoxinA (Dysport (), OnabotulinumtoxinA (Botox (), and IncobotulinumtoxinA (Xeomin () Neurotoxin Content and Potential Implications for Duration of Response in Patients","volume":"10","author":"Field","year":"2018","journal-title":"Toxins"},{"key":"R11-20250803","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1016\/j.tripleo.2009.03.021","article-title":"Injection of botulinum toxin type A (BOTOX) into trigger zone of trigeminal neuralgia as a means to control pain","volume":"109","author":"Ngeow","year":"2010","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol, Endodontol"},{"key":"R12-20250803","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.oooo.2016.11.009","article-title":"Botulinum toxin in the management of head and neck disorders","volume":"123","author":"Nagi","year":"2017","journal-title":"Oral Surgery, Oral Med, Oral Pathol aOral Radiol"},{"key":"R13-20250803","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.tripleo.2007.02.004","article-title":"The therapeutic use of botulinum toxin in cervical and maxillofacial conditions: an evidence-based review","volume":"104","author":"Ihde","year":"2007","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol, Endodontol"},{"key":"R14-20250803","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/jocd.13266","article-title":"Complications of botulinum toxin and fillers: A narrative review","volume":"19","author":"Kassir","year":"2020","journal-title":"J Cosmet Dermatol"},{"key":"R15-20250803","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S0278-2391(03)00153-8","article-title":"Type A botulinum toxin in the treatment of chronic facial pain associated with masticatory hyperactivity","volume":"61","author":"von Lindern","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"R16-20250803","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1046\/j.1526-4610.2002.02234.x","article-title":"Relief of Tension-type Headache Symptoms in Subjects with Temporomandibular Disorders Treated with Botulinum Toxin-A","volume":"42","author":"Freund","year":"2002","journal-title":"Headache"},{"key":"R17-20250803","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ijom.2016.11.004","article-title":"Clinical outcomes of Botox injections for chronic temporomandibular disorders: do we understand how Botox works on muscle, pain, and the brain?","volume":"46","author":"Connelly","year":"2017","journal-title":"Int J Oral Maxillofac Surg"},{"key":"R18-20250803","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.ijom.2017.04.020","article-title":"Localized myofascial pain responds better than referring myofascial pain to botulinum toxin injections","volume":"46","author":"Abboud","year":"2017","journal-title":"Int J Oral Maxillofac Surg"},{"key":"R19-20250803","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1179\/crn.2008.017","article-title":"Efficacy of Botulinum Toxin in Treating Myofascial Pain in Bruxers: A Controlled Placebo Pilot Study","volume":"26","author":"Guarda-Nardini","year":"2008","journal-title":"Cranio"},{"key":"R20-20250803","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jormas.2019.02.015","article-title":"The use of botulinum toxin-a in the treatment of muscular temporomandibular joint disorders","volume":"120","author":"Sipahi Calis","year":"2019","journal-title":"Journal of Stomatology Oral Maxillofac Surg"},{"key":"R21-20250803","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1016\/j.pain.2011.03.036","article-title":"Efficacy of botulinum toxin type A for treatment of persistent myofascial TMD pain: A randomized, controlled, double-blind multicenter study","volume":"152","author":"Ernberg","year":"2011","journal-title":"Pain"},{"key":"R22-20250803","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/AJP.0b013e31820215f5","article-title":"Temporomandibular disorders and associated clinical comorbidities","volume":"27","author":"Hoffmann","year":"2011","journal-title":"Clin J Pain"},{"key":"R23-20250803","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.cden.2013.04.007","article-title":"Disorders of the masticatory muscles","volume":"57","author":"De Rossi","year":"2013","journal-title":"Dent Clin North Am"},{"issue":"(1.)","key":"R24-20250803","article-title":"Specific and number of comorbidities are associated with increased levels of temporomandibular pain intensity and duration","volume":"16","author":"Dahan","year":"2015","journal-title":"J Headache Pain"},{"key":"R25-20250803","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/joor.12539","article-title":"Pharmacological treatment of oro-facial pain - health technology assessment including a systematic review with network meta-analysis","volume":"44","author":"H\u00e4ggman-Henrikson","year":"2017","journal-title":"J Oral Rehabil"},{"key":"R26-20250803","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1601-0825.2007.01352.x","article-title":"The emerging role of botulinum toxin in the treatment of temporomandibular disorders","volume":"13","author":"Song","year":"2007","journal-title":"Oral Dis"}],"container-title":["Journal of Craniofacial Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/SCS.0000000000008331","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T17:07:52Z","timestamp":1754240872000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/SCS.0000000000008331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,5]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/scs.0000000000008331","relation":{},"ISSN":["1049-2275","1536-3732"],"issn-type":[{"value":"1049-2275","type":"print"},{"value":"1536-3732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,5]]}}}